Please use this identifier to cite or link to this item:
|Title:||A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children|
Varicella zoster virus
|Source:||Lau, Y.-L., Lee, T.-L., Vessey, S.J.R., Chan, I.S.F., Chan, C.Y., Kaplan, K.M., Distefano, D.J., Harmon, A.L., Golie, A., Hartzel, J., Xu, J., Li, S., Matthews, H., Sadoff, J.C., Shaw, A., Huang, L.-M., Lee, C.-Y., Lin, T.-Y., Lee, B.W., Kwan, K., Kasim, S.M. (2002). A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX™ in healthy children. Vaccine 20 (23-24) : 2942-2949. ScholarBank@NUS Repository. https://doi.org/10.1016/S0264-410X(02)00245-1|
|Abstract:||This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX™ [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX™, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively. © 2002 Elsevier Science Ltd. All rights reserved.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2018
WEB OF SCIENCETM
checked on Jan 30, 2018
checked on Feb 19, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.